A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy

Inclusion Criteria:

- Diagnosis of hepatocellular carcinoma (HCC) ≥ 2cm based on:

- Biopsy OR

- Radiological evidence of HCC by contrast-enhanced CT scan or contrast-enhanced AND

- Blood test positive for Hepatitis B or C AND

- Alpha fetoprotein above > 400 mg/L

- Not appropriate for curative surgery

- Screening Blood Pressure <150/100 mmHg, Left Ventricular Ejection Fraction (LVEF)
>50%

Exclusion Criteria:

- Heart Attack within 12 months, uncontrolled chest pain within 6 months

- Ascites resistant to diuretic medication therapy

- Portal-systemic encephalopathy

- Portal hypertension with bleeding esophageal or gastric varices within the past 2
months

- Deficiency of sodium in the blood with sodium < 125 mEq/L

- Subjects with serious non-healing wounds, ulcers or bone fractures